Provided by Tiger Trade Technology Pte. Ltd.

Ocugen

1.40
+0.04002.94%
Post-market: 1.40-0.0001-0.01%19:57 EDT
Volume:4.59M
Turnover:6.43M
Market Cap:473.92M
PE:-5.49
High:1.43
Open:1.39
Low:1.38
Close:1.36
52wk High:2.73
52wk Low:1.00
Shares:338.52M
Float Shares:327.56M
Volume Ratio:1.23
T/O Rate:1.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2551
EPS(LYR):-0.2260
ROE:-660.00%
ROA:-48.44%
PB:-28.63
PE(LYR):-6.19

Loading ...

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Aug 04

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Aug 01

Ocugen to Present Modifier Gene Therapy Platform at Oppenheimer Biotech Summit

Reuters
·
Jul 31

Ocugen to Participate in Upcoming August Investor Conferences

GlobeNewswire
·
Jul 31

Ocugen Announces Special Shareholder Meeting

Reuters
·
Jul 31

Ocugen Inc. Stock Falls Wednesday, Underperforms Market

Dow Jones
·
Jul 30

Ocugen - to Initiate Ocu410 Phase 3 Trial in Q3 2026, Bla Filing Anticipated in 2028

THOMSON REUTERS
·
Jul 29

Ocugen Announces That the U.S. Food and Drug Administration Has Granted Ocu410 Regenerative Medicine Advanced Therapy (Rmat) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

THOMSON REUTERS
·
Jul 29

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

GlobeNewswire
·
Jul 29

Ocugen Inc. Stock Rises Monday, Outperforms Market

Dow Jones
·
Jul 28

Ocugen Inc. Stock Falls Friday, Underperforms Market

Dow Jones
·
Jul 25

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Jul 24

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 21

Ocugen Announces Special Shareholder Meeting

Reuters
·
Jul 21

Ocugen Inc. Stock Falls Thursday, Underperforms Market

Dow Jones
·
Jul 17

Ocugen Inc. Stock Falls Monday, Underperforms Market

Dow Jones
·
Jul 14

Ocugen inks OCU400 licensing deal for MENA

TIPRANKS
·
Jul 14

U.S. Stocks on the Move-american Express, Deckers, Q32 Bio

Reuters
·
Jul 13

Ocugen announces $4M OCU400 license agreement with Roots Pharmaceutical

TIPRANKS
·
Jul 13

Ocugen Rises on Mideast Licensing Deal for Experimental Blindness Gene Therapy

Reuters
·
Jul 13